- Home
- GMAB vs POOL Comparison
GMAB vs POOL Comparison
Compare GMAB & POOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- POOL
- Stock Information
- Founded
- GMAB 1999
- POOL 1993
- Country
- GMAB Denmark
- POOL United States
- Employees
- GMAB N/A
- POOL N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- POOL Industrial Specialties
- Sector
- GMAB Health Care
- POOL Consumer Discretionary
- Exchange
- GMAB Nasdaq
- POOL Nasdaq
- Market Cap
- GMAB 13.7B
- POOL N/A
- IPO Year
- GMAB N/A
- POOL 1995
- Fundamental
- Price
- GMAB $20.72
- POOL $305.30
- Analyst Decision
- GMAB Buy
- POOL Buy
- Analyst Count
- GMAB 9
- POOL 8
- Target Price
- GMAB $39.17
- POOL $347.63
- AVG Volume (30 Days)
- GMAB 1.5M
- POOL 725.6K
- Earning Date
- GMAB 08-07-2025
- POOL 07-24-2025
- Dividend Yield
- GMAB N/A
- POOL 1.64%
- EPS Growth
- GMAB 276.80
- POOL N/A
- EPS
- GMAB 18.36
- POOL 10.70
- Revenue
- GMAB $3,230,902,140.00
- POOL $5,261,669,000.00
- Revenue This Year
- GMAB $747.74
- POOL $2.26
- Revenue Next Year
- GMAB $14.81
- POOL $4.25
- P/E Ratio
- GMAB $1.13
- POOL $28.42
- Revenue Growth
- GMAB 25.43
- POOL N/A
- 52 Week Low
- GMAB $17.24
- POOL $282.22
- 52 Week High
- GMAB $28.56
- POOL $395.60
- Technical
- Relative Strength Index (RSI)
- GMAB 41.92
- POOL 45.95
- Support Level
- GMAB $20.39
- POOL $286.00
- Resistance Level
- GMAB $20.75
- POOL $302.34
- Average True Range (ATR)
- GMAB 0.32
- POOL 6.79
- MACD
- GMAB -0.23
- POOL 0.30
- Stochastic Oscillator
- GMAB 7.98
- POOL 42.47
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.